TriangleNCT01078974 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- true
- limitations And Caveats
- description
- Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare.
- point Of Contact
- steven_treon@dfci.harvard.edu
- organization
- Dana-Farber Cancer Institute
- phone
- 617-632-2681
- title
- Steven P. Treon
Complete source fields
- certain Agreement
- pi Sponsor Employee
- true
- limitations And Caveats
- description
- Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare.
- point Of Contact
- steven_treon@dfci.harvard.edu
- organization
- Dana-Farber Cancer Institute
- phone
- 617-632-2681
- title
- Steven P. Treon
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice